J
Joseph Armstrong Martin
Researcher at Hoffmann-La Roche
Publications - 13
Citations - 426
Joseph Armstrong Martin is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Polymerase & Hepatitis C virus. The author has an hindex of 6, co-authored 13 publications receiving 423 citations. Previous affiliations of Joseph Armstrong Martin include Cardiff University.
Papers
More filters
Journal ArticleDOI
Application of the phosphoramidate ProTide approach to 4'-azidouridine confers sub-micromolar potency versus hepatitis C virus on an inactive nucleoside.
Plinio Perrone,G Luoni,M. R. Kelleher,Felice Daverio,A Angell,S. Mulready,Costantino Congiatu,S. Rajyaguru,Joseph Armstrong Martin,V. Leveque,S. Le Pogam,Najera Isabel,Klaus Klumpp,David Bernard Smith,Christopher McGuigan +14 more
TL;DR: Results confirm that phosphoramidate ProTides can deliver monophosphates of ribonucleoside analogues and suggest a potential path to the generation of novel antiviral agents against HCV infection.
Patent
4'-substituted nucleoside derivatives as inhibitors of hcv rna replication
Devos Rene Robert,Hobbs Christopher John,Jiang Wen-Rong,Joseph Armstrong Martin,Merrett John Herbert,Najera Isabel,Nobuo Shimma,Takuo Tsukuda +7 more
TL;DR: In this article, the use of nucleoside derivatives of formula I for the treatment of diseases mediated by the hepatitis C Virus (HCV) for the preparation of a medicament for such treatment and to pharmaceutical compositions containing such compounds.
Journal ArticleDOI
First example of phosphoramidate approach applied to a 4'-substituted purine nucleoside (4'-azidoadenosine): conversion of an inactive nucleoside to a submicromolar compound versus hepatitis C virus.
Plinio Perrone,Felice Daverio,Rocco Valente,Sonal Rajyaguru,Joseph Armstrong Martin,Vincent Leveque,Sophie Le Pogam,Najera Isabel,Klaus Klumpp,David Bernard Smith,Christopher McGuigan +10 more
TL;DR: Phosphoramidates achieved a significant improvement in antiviral potency over the parent nucleoside 4'-azidoadenosine with no increase in cytotoxicity.
Patent
Anti-viral nucleosides
TL;DR: In this paper, compositions and methods for inhibiting HCV and treating HCV-mediated diseases, processes for making the compounds and synthetic intermediates employed in the process are discussed. But none of them are described in detail.
Patent
Antiviral 4'-azido-nucleosides
TL;DR: In this article, compositions and methods for inhibiting HCV and treating HCV-mediated diseases, processes for making the compounds and synthetic intermediates employed in the process are discussed and discussed.